Prospective study of safety, immunogenicity, and efficacy of inactivated COVID-19 vaccine in tuberous sclerosis complex children on sirolimus

Prospective study of safety, immunogenicity, and efficacy of inactivated COVID-19 vaccine in tuberous sclerosis complex children on sirolimus

While sirolimus is widely used in tuberous sclerosis complex (TSC), its impact on coronavirus disease 2019 (COVID-19) vaccination remains unclear. To evaluate the safety, immunogenicity, and efficacy of inactivated COVID-19 vaccine on the children with TSC on sirolimus, we conducted a prospective co...

Full description

Saved in:
Bibliographic Details
Main Authors: Sufang Lin, Xia Zhao, Lin Li, Qiru Su, Weiwei Long, Xiaoqin Tian, Jinghua Ye, Bixia Yuan, Yan Hu, Jianxiang Liao, Hongbing Zhang
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
COVID-19
vaccine
immunogenicity
efficacy
tuberous sclerosis complex
sirolimus
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2025.2535120
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items